A key part of it is regulatory and another part is economic. The prices of the generic products have been reduced substantially, and the regulatory burden to support them has gone up enormously.
In the plans that we're hearing of from Health Canada, the cost of maintaining products on the market—which are already approved—is going up substantially.
While the margins are going down, the cost to operate or to keep it are going up.
That's one of those points where I say the big picture is being lost in the cost recovery.